Ies show that frailty is associated with increased mortality so it is indeed interesting that this audit has shown no difference between the two groups.References 1. Rockwood, Song, McKnight. A global clinical measure of fitness and frailty in elderly people.CMAJ: 2005, vol 173 no.5 2. The Edmonton Frailty Scale. Age and Ageing, volume 35.A940 Outcomes in elderly patients admitted to ICU C. Castro

Ly increasing. This audit aimed to look retrospectively at our admissions to Intensive Care, to categorise them into frail or non frail, and evaluate how frailty correlated with ICU length of stay and mortality Methods: A retrospective case note review of all patients admitted to Intensive Care over a six month period in the Victoria Infirmary and then Queen Elizabeth University hospital in Glasgo

Onstrated since all of the ABP 501 lots fell within the quality range established based on the adalimumab (US) lots tested. Another mechanism for inducing cell death is the induction of CDC in cells expressing mbTNFa. A comparison of the CDC activity of ABP 501 to that of adalimumab (US) and adalimumab (EU) using MT-3 cells as target cells was conducted. Mean (three independent experiments) percen

Ver the age of 65. Interestingly, there is no significant difference between the non frail and frail groups of patients admitted to intensive care. This may be because of small sample size. The length of stay of the frail patient is shorter and this may be because as intensivists we are better at treatment limitation in this group of patients. No difference in overall mortality suggests that the p

Ver the age of 65. Interestingly, there is no significant difference between the non frail and frail groups of patients admitted to intensive care. This may be because of small sample size. The length of stay of the frail patient is shorter and this may be because as intensivists we are better at treatment limitation in this group of patients. No difference in overall mortality suggests that the p

Mith, T. 1987. Eukaryotes with no mitochondria. Nature 326: 332?33. 30. Cavalier-Smith, T. 1987. The origin of eukaryotic and archaebacterial cells. Ann. N. Y. Acad. Sci. 503:17?4. 30a.Cavalier-Smith, T. 1991. The evolution of cells, p. 271?04. In S. Osawa and T. Honjo (ed.), Evolution of life. Springer-Verlag, Tokyo, Japan. 31. Cavalier-Smith, T. 1992. Origins of secondary metabolism. Ciba Found.

Rm the safety and efficacy profile of ABP 501. In a phase I human pharmacokinetic study, ABP 501 has been shown to be similar to adalimumab (US) and adalimumab (EU) [26, 27]. Clinical studies designed to assess the similarity of ABP 501 relative to the adalimumab reference product for the treatment of moderate to severe plaque psoriasis [28, 29] and moderate to severe rheumatoid arthritis [30, 31]

Rm the safety and efficacy profile of ABP 501. In a phase I human pharmacokinetic study, ABP 501 has been shown to be similar to adalimumab (US) and adalimumab (EU) [26, 27]. Clinical studies designed to assess the similarity of ABP 501 relative to the adalimumab reference product for the treatment of moderate to severe plaque psoriasis [28, 29] and moderate to severe rheumatoid arthritis [30, 31]